Third-line treatment in metastatic renal cell carcinoma and bone metastases

le Heng, Daniel Y. C.
Foilsithe in Can Urol Assoc J (2015)

The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma

le Heng, Daniel Y.C.
Foilsithe in Can Urol Assoc J (2016)

Contemporary Treatment of Metastatic Renal Cell Carcinoma

le Stukalin, Igor, Alimohamed, Nimira, Heng, Daniel Y.C.
Foilsithe in Oncol Rev (2016)

Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience

le Ruiz-Morales, Jose Manuel, Heng, Daniel Y.C.
Foilsithe in Ther Adv Urol (2016)

Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions

le Heng, Daniel Y.C., Kollmannsberger, Christian, Chi, Kim N.
Foilsithe 2010

Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer

le Tang, Patricia A., Heng, Daniel Y. C., Choueiri, Toni K.
Foilsithe 2011

Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated With Targeted Therapies

le Yip, Steven M., Heng, Daniel Y.C., Tang, Patricia A.
Foilsithe in J Kidney Cancer VHL (2016)

Personalized Management of Advanced Kidney Cancer

le Graham, Jeffrey, Heng, Daniel Y. C., Brugarolas, James, Vaishampayan, Ulka
Foilsithe in Am Soc Clin Oncol Educ Book (2018)

In Reply

le de Velasco, Guillermo, Culhane, Aedín C., Heng, Daniel Y.C., Signoretti, Sabina, Choueiri, Toni K.
Foilsithe in Oncologist (2017)

Disease characteristics and survival outcomes of extragonadal primary germ cell tumour in two Canadian tertiary cancer centres

le Ko, Jenny J., Asif, Tehmina, Li, Haocheng, Alimohamed, Nimira, Nguyen, Phuong Thao, Heng, Daniel Y.C.
Foilsithe in Can Urol Assoc J (2016)

Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma

le McKay, Rana R., Lin, Xun, Perkins, Julia J., Heng, Daniel Y. C., Simantov, Ronit, Choueiri, Toni K.
Foilsithe 2014

Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma

le Lalani, Aly-Khan A., Bakouny, Ziad, Farah, Subrina, Donskov, Frede, Dudani, Shaan, Heng, Daniel Y. C., Choueiri, Toni K.
Foilsithe in JAMA Oncol (2021)

A Randomized Phase II Study of AGS‐16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma

le Kollmannsberger, Christian, Choueiri, Toni K., Heng, Daniel Y.C., George, Saby, Jie, Fei, Croitoru, Ruslan, Poondru, Srinivasu, Thompson, John A.
Foilsithe in Oncologist (2021)

Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial

le Ristau, Benjamin T., Manola, Judi, Haas, Naomi B., Heng, Daniel Y. C., Messing, Edward M., Wood, Christopher G., Kane, Christopher J., DiPaola, Robert S., Uzzo, Robert G.
Foilsithe in J Urol (2017)

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors

le Sander, Michael S., Stukalin, Igor, Vallerand, Isabelle A., Goutam, Siddhartha, Ewanchuk, Benjamin W., Meyers, Daniel E., Pabani, Aliyah, Morris, Don G., Heng, Daniel Y. C., Cheng, Tina
Foilsithe in Cancer Med (2021)

Progression-Free Survival as a Predictor of Overall Survival in Metastatic Renal Cell Carcinoma Treated With Contemporary Targeted Therapy

le Heng, Daniel Y. C., Xie, Wanling, Bjarnason, Georg A., Vaishampayan, Ulka, Tan, Min-Han, Knox, Jennifer, Donskov, Frede, Wood, Lori, Kollmannsberger, Christian, Rini, Brian I., Choueiri, Toni K.
Foilsithe 2010

Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma

le Choueiri, Toni K., Lim, Zita Dubauskas, Hirsch, Michelle S., Tamboli, Pheroze, Jonasch, Eric, McDermott, David F., Cin, Paola Dal, Corn, Paul, Vaishampayan, Ulka, Heng, Daniel Y.C., Tannir, Nizar M.
Foilsithe in Cancer (2010)

The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institut...

le Kaiser, Jeenan, Li, Haocheng, North, Scott A., Leibowitz-Amit, Raya, Seah, Jo-An, Morshed, Nisha, Chau, Caroline, Lee-Ying, Richard, Heng, Daniel Y.C., Sridhar, Srikala, Crabb, Simon J., Alimohamed, Nimira S.
Foilsithe in Bladder Cancer (2018)

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors

le Meyers, Daniel E., Stukalin, Igor, Vallerand, Isabelle A., Lewinson, Ryan T., Suo, Aleksi, Dean, Michelle, North, Scott, Pabani, Aliyah, Cheng, Tina, Heng, Daniel Y.C., Bebb, D. Gwyn, Morris, Don G.
Foilsithe in Cancers (Basel) (2019)

Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma

le Gupta, Alind, Arora, Paul, Brenner, Darren, Vanderpuye-Orgle, Jacqueline, Boyne, Devon J., Edmondson-Jones, Mark, Parkhomenko, Elena, Stevens, Warren, Dudani, Shaan, Heng, Daniel Y. C., Wagner, Samuel, Borrill, John, Wu, Elise
Foilsithe in JCO Clin Cancer Inform (2021)